Latest stories on FATE
FATE Reiterated by Wedbush -- Price Target Maintained at $7.00
GuruFocus52 · neutralanalyst
Fate Therapeutics presents updated FT819 data at Kidney Week
The Fly58 · neutralproduct/pr
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
Business Insider74 · bullishproduct/pr
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
GlobeNewswire74 · bullishproduct/pr
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
GlobeNewswire56 · neutralgeneral
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Business Insider56 · neutralgeneral
FATE THERAPEUTICS INC (FATE) files 8-K
SEC 8-K50 · neutralgeneral
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Business Insider67 · bullishgeneral
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
GlobeNewswire67 · bullishgeneral
Fate Therapeutics announces clinical data from FT819 study
The Fly59 · neutralproduct/pr
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Business Insider56 · neutralgeneral
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
Seeking Alpha63 · neutralproduct/pr
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
TipRanks63 · neutralproduct/pr
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
The Fly48 · neutralearnings
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
The Fly61 · neutralanalyst
Fate Therapeutics intiates first patient in RECLAIM-LN trial
The Fly56 · neutralproduct/pr
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
StockTitan63 · neutralproduct/pr
Fate Therapeutics GAAP EPS of -$0.25 beats by $0.02, revenue of $2.08M beats by $0.81M
Seeking Alpha56 · neutralearnings